» Articles » PMID: 27016266

Adverse Drug Event Reporting Systems: a Systematic Review

Overview
Specialty Pharmacology
Date 2016 Mar 27
PMID 27016266
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: Adverse drug events (ADEs) are harmful and unintended consequences of medications. Their reporting is essential for drug safety monitoring and research, but it has not been standardized internationally. Our aim was to synthesize information about the type and variety of data collected within ADE reporting systems.

Methods: We developed a systematic search strategy, applied it to four electronic databases, and completed an electronic grey literature search. Two authors reviewed titles and abstracts, and all eligible full-texts. We extracted data using a standardized form, and discussed disagreements until reaching consensus. We synthesized data by collapsing data elements, eliminating duplicate fields and identifying relationships between reporting concepts and data fields using visual analysis software.

Results: We identified 108 ADE reporting systems containing 1782 unique data fields. We mapped them to 33 reporting concepts describing patient information, the ADE, concomitant and suspect drugs, and the reporter. While reporting concepts were fairly consistent, we found variability in data fields and corresponding response options. Few systems clarified the terminology used, and many used multiple drug and disease dictionaries such as the Medical Dictionary for Regulatory Activities (MedDRA).

Conclusion: We found substantial variability in the data fields used to report ADEs, limiting the comparability of ADE data collected using different reporting systems, and undermining efforts to aggregate data across cohorts. The development of a common standardized data set that can be evaluated with regard to data quality, comparability and reporting rates is likely to optimize ADE data and drug safety surveillance.

Citing Articles

Frequency of self-reported persistent post-treatment genital hypoesthesia among past antidepressant users: a cross-sectional survey of sexual and gender minority youth in Canada and the US.

Pirani Y, Delgado-Ron J, Marinho P, Gupta A, Grey E, Watt S Soc Psychiatry Psychiatr Epidemiol. 2024; .

PMID: 39302425 DOI: 10.1007/s00127-024-02769-0.


A discovery and verification approach to pharmacovigilance using electronic healthcare data.

Dijkstra L, Schink T, Linder R, Schwaninger M, Pigeot I, Wright M Front Pharmacol. 2024; 15:1426323.

PMID: 39295940 PMC: 11408326. DOI: 10.3389/fphar.2024.1426323.


Evaluating the Outcome and Patient Safety of Methotrexate, Doxorubicin, and Cisplatin Regimen for Chemotherapy in Osteosarcoma: A Meta-Analysis.

Ismail M, Wiratnaya I, Raditya R Asian Pac J Cancer Prev. 2024; 25(5):1497-1505.

PMID: 38809621 PMC: 11318805. DOI: 10.31557/APJCP.2024.25.5.1497.


The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration.

Fusaroli M, Salvo F, Begaud B, Alshammari T, Bate A, Battini V Drug Saf. 2024; 47(6):585-599.

PMID: 38713347 PMC: 11116264. DOI: 10.1007/s40264-024-01423-7.


Sex and gender differences and pharmacovigilance: a knot still to be untied.

Sportiello L, Capuano A Front Pharmacol. 2024; 15:1397291.

PMID: 38694914 PMC: 11061534. DOI: 10.3389/fphar.2024.1397291.


References
1.
van der Linden C, Jansen P, van Marum R, Grouls R, Korsten E, Egberts A . Recurrence of adverse drug reactions following inappropriate re-prescription: better documentation, availability of information and monitoring are needed. Drug Saf. 2010; 33(7):535-8. DOI: 10.2165/11532350-000000000-00000. View

2.
Bates D, Cullen D, Laird N, Petersen L, Small S, Servi D . Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA. 1995; 274(1):29-34. View

3.
Tamblyn R, Laprise R, Hanley J, Abrahamowicz M, Scott S, Mayo N . Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001; 285(4):421-9. DOI: 10.1001/jama.285.4.421. View

4.
Arts D, de Keizer N, Scheffer G . Defining and improving data quality in medical registries: a literature review, case study, and generic framework. J Am Med Inform Assoc. 2002; 9(6):600-11. PMC: 349377. DOI: 10.1197/jamia.m1087. View

5.
Bailey C, Peddie D, Wickham M, Badke K, Small S, Doyle-Waters M . Adverse drug event reporting systems: a systematic review. Br J Clin Pharmacol. 2016; 82(1):17-29. PMC: 4917803. DOI: 10.1111/bcp.12944. View